Research Papers:
Alu methylation serves as a biomarker for non-invasive diagnosis of glioma
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2445 views | HTML 2079 views | ?
Abstract
Jian Chen1,*, Wei Huan2,*, Hao Zuo2, Longxiang Zhao2, Chuanjun Huang2, Xiaojiang Liu2, Shiqiang Hou2, Jing Qi2, Wei Shi1,2
1Department of Neurological Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, China
2Comprehensive Surgical Laboratory, Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, China
*These authors have contributed equally to this work
Correspondence to:
Wei Shi, e-mail: [email protected]
Jing Qi, e-mail: [email protected]
Keywords: glioma, cell-free DNA, Alu, methylation, liquid chip
Received: July 23, 2015 Accepted: March 04, 2016 Published: March 23, 2016
ABSTRACT
Current techniques for diagnosing glioma are invasive and do not accurately predict prognosis. We developed a novel, non-invasive liquid chip assay to diagnose glioma and predict prognosis. Using this method, we determined the methylation state of the Alu element in cell-free DNA extracted from the serum of 109 glioma patients. Controls included 56 patients with benign intracranial tumors and 50 healthy subjects. Matched tumor tissues were processed for 36 patients. The cfDNA from glioma patients showed lower levels of Alu methylation than the controls (P<0.01). Alu methylation was also lower in high-grade than low-grade gliomas (P<0.01), indicating that Alu methylation correlates negatively with disease severity. Moreover, Alu methylation correlated positively with survival (P<0.01). These findings suggest high-throughput liquid chip could serve as a non-invasive diagnostic assay for glioma.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8318